Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 17/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963208 | 0.84 | KDM4E (0.43) | KMT2AKDM4EALDH1A1NR3C1SMN1; SMN2 | |
| SCHEMBL17981692 | 0.83 | KDM4E (0.41) | KMT2AKDM4EALDH1A1NR3C1 | |
| SCHEMBL17981685 | 0.83 | KMT2A (0.42) | KMT2AKDM4EALDH1A1NR3C1 | |
| SCHEMBL20413602 | 0.81 | NR3C1 (0.69) | KDM4EALDH1A1NR3C1 | |
| SCHEMBL20413411 | 0.79 | NR3C1 (0.70) | NR3C1 | |
| SCHEMBL20413394 | 0.78 | NR3C1 (0.71) | KMT2AKDM4EALDH1A1NR3C1SMN1; SMN2 | |
| SCHEMBL17980464 | 0.77 | NR3C1 (0.67) | NR3C1 | |
| SCHEMBL20413370 | 0.77 | NR3C1 (0.59) | NR3C1 | |
| SCHEMBL20413603 | 0.76 | NR3C1 (0.69) | KDM4EALDH1A1NR3C1SMN1; SMN2 | |
| SCHEMBL20413366 | 0.76 | NR3C1 (0.69) | KDM4ENR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| WO-2016123392-A2 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | KMT2A 3251/4885KDM4E 3498/4885ALDH1A1 3369/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | KMT2A 3527/4885KDM4E 3499/4885ALDH1A1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.